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Very few data are available from large series on the frequency and the time trends of pregnancy 
associated cancers (PAC), in particular few data are available from Southern European countries, an 
area characterized by different cancer incidence that north European and American ones. In this 




This is a population based linkage study using the regional hospital discharge forms (HDF)  
database of four Italian regions (Piemonte and Veneto (Northern Italy), Tuscany (Central Italy) and 
Puglia (Southern Italy), regions with more than 17,000,000 inhabitants. 
All resident women with a HDF reporting a birth or abortion in the considered period were 
identified. Risk of developing a pregnancy related cancer was calculated as the ratio of the number 
of pregnancy  related cancers to the total number of pregnancies.  
During the period 2003-15 for Piemonte and Puglia, 2006-2015 for Tuscany and 2005-2015 for 
Veneto  a total of 2297648 pregnancies were identified. Overall, the PAC frequency  was 
 134,1 per 100,000 pregnancies: the value ranged from 127,1 in Puglia to 157,3 in Tuscany.   
The frequency for 100,000 pregnancies was 66,4 in women aged less than 30 years and increased 
with age being 275,6 among women aged 40 years or more. Approximately two thirds of cancers 
were associated with pregnancies resulting in a delivery and one third with pregnancies resulting 





This large population-based study offers sound estimates of the frequency of PAC in Italy and 





Pregnancy-associated cancer (PAC) is generally defined as a diagnosis of cancer made during 
pregnancy. Even in cancers diagnosed in the year after the end of the pregnancy, the tumor could 
have originated before or during the pregnancy. Moreover, the pregnancy may have influenced the 
timing of the diagnosis, thus diagnosis within 12 months of delivery/abortion is considered among 
PAC. 
In the recent years great attention has being given to PAC. The diagnosis of a neoplastic disease in 
pregnancy, though rare, is a condition of great human and social relevance and of complex 
management. In many cases the diagnosis of cancer during pregnancy is delayed: signs and 
symptoms may overlap and be masked by physiological changes that occur during pregnancy [1].   
Moreover, systemic medications for cancers have many potential risks and complications for the 
mother and the baby. A recent cohort study shows that babies exposed to antenatal chemotherapy 
might be more likely to develop complications specifically for gestational age and admission in 
neonatal intensive care unit [2].  
Although an incidence of about 1 case out of 1000 pregnancies is generally reported [3], few 
epidemiological studies have estimated the true occurrence of PAC [4,5]. 
The crude incidence rates were 1, 4 /1000 maternities in Australia [4], and 0.9/1000 births in 
California [5]. Recently, the PAC incidence in Denmark has been set at 0.89/1000 pregnancies, with 
an estimated annual 1.6% increase[6].   
Scanty information is available on the frequency of PAC in Southern European countries. Some of 
us have recently published an analysis from Lombardy, a Northern Italian region [7]. This analysis, 
although based on a population of about ten millions inhabitants, included only 1475 PAC cases. 
Further, no data have been published from Central or Southern Italy, areas characterized by different 
reproductive patterns and incidence of neoplasia. 
In order to offer more sound estimates of PAC frequency and data from different Italian areas 
representative of all the three main geographic areas (North Centre and South) characterized by 
different lifestyle habits and incidence of cancer [8], we have evaluated the incidence and 
determinants of PAC by cancer site in Veneto, Piemonte, Tuscany and Puglia, four Italian regions 







The present analysis included information from four Italian regions (Piemonte and Veneto 
(Northern Italy), Toscana (Central Italy) and Puglia (Southern Italy). The participating regions have 
overall more than 17,000,000 inhabitants. 
To identify all pregnancies and PAC, we used the regional hospital discharge forms [Scheda di 
Dimissione Ospedaliera (SDO)] database, which stores hospital discharge records from all hospitals 
placed in the participating regions. These forms contain information about patients and their 
hospitalization (both ordinary and in day hospital), including, among others, the unique anonymous 
patient’s identification code, demographic characteristics, admission and discharge dates, the main 
diagnosis and 5 secondary diagnoses [coded according to the International Classification of 
Disease, Ninth Revision (ICD-9)], date and type of up to 5 interventions, and hospitalization-related 
costs [coded according to the national diagnosis-related group (DRG) system] [9].  
Pregnancies were identified by selecting all SDOs reporting DRG codes related to both deliveries 
(DRG codes: 370-375) and abortions (DRG codes: 380-381). We further verified that each selected 
SDO reported diagnoses or interventions related to delivery or abortion. We defined the discharge 
date of hospitalization as the date of pregnancy outcome (delivery or abortion). Pregnancy 
associated cancer was defined by any diagnosis of malignant cancer during pregnancy; if it occurred 
within 9 and 3 months before the date of delivery or abortion, respectively, or if it occurred within 
12 months after the pregnancy outcome. Cancers were identified by selecting all SDOs reporting a 
diagnosis of malignant cancer (ICD-9 codes:140.-208.) in the main or secondary diagnoses. To 
select only incident cases, we did not consider SDOs in which the cancer was recorded as secondary 
diagnosis or if a previous SDO reported cancer as the main diagnosis.  
For each woman, we selected the first SDO reporting a cancer diagnosis during the observation 
period, and we defined the admission date as the date of cancer diagnosis. We classified the cancer 
site on the basis of ICD-9 codes, combining them into the following anatomic groups: head and 
neck (ICD-9 140.-149., 160.), stomach (ICD-9 151.), colorectum (ICD-9 153.-154.), pancreas 
(ICD-9 157.), other gastrointestinal tract (ICD-9 150., 152., 156., 158.-159.), lung (ICD-9 162.), 
other respiratory tract (ICD-9 161., 163., 165.), skeletal/connective tissue (ICD-9 170.-171.), 
melanoma (ICD-9 172.), skin (excluding melanoma) (ICD-9 173.), breast (ICD-9 174.), uterus 
(ICD-9 179.), cervix (ICD-9 180.), placenta (ICD-9 181.), endometrium (ICD-9 182.), ovary (ICD-
9 183.), other gynecologic tract (ICD-9 184.), urinary tract (ICD-9 188., 189.1-189.4, 189.8-189.9), 
kidney (ICD-9 189.0), nervous system (ICD-9 191.-192.), thyroid (ICD-9 193.), lymphoma (ICD-9 
200.-202.), multiple myeloma (ICD-9 203.), leukemia (ICD-9 204.-208.), and other or ill-defined 
(ICD-9 164., 190., 194.-199.).  
We categorized cancers with respect to the period of diagnosis: during pregnancy, if the date of 
cancer diagnosis preceded the date of pregnancy outcome, and after pregnancy, otherwise.  
We computed the ratio of the number of pregnancy-related cancers to the total number of 
pregnancies [4,5].  
The incidence rate of pregnancy-related cancer will be computed as the ratio of the number of 
pregnancy-related cancers to the total years of follow-up (15 months for an abortion, 21 months for 
a delivery). 
If a pregnancy-associated cancer occurred, follow-up was stopped at the date of cancer diagnosis. 
We stratified the incidence rate of pregnancy-related cancers by calendar year, age at pregnancy, 




During the period 2003-2015 (2003-15 for Piemonte and Puglia 2006-2015 for Tuscany and 2005-
2015 for Veneto) a total of 2.297.648 pregnancies were identified from the SDO database that 
referred to women aged between 12 and 55 years and residing in the considered Regions. 
Among these pregnancies, 1.132.283 ended with a delivery and 795.769 with an abortion. 
After exclusion of women with: -a diagnosis of cancer as a secondary diagnosis, -a primary cancer 
diagnosis before the pregnancy, and women for which the cancer site was unclear, we identified 
3058 women with a pregnancy related cancer diagnosis. 
Table 1 shows the number of cases and the frequency per 100,000 pregnancies in the total series and 
according to Region  and selected factors. 
Overall, the risk was 134,8 per 100,000 pregnancies: the value ranged from 127,1 in Puglia to 157,3 
in Tuscany.   
Slightly less than 50% of women diagnosed with cancer were aged less than 35 years. The risk for 
100,000 pregnancies was 66,4 in women aged less than 30 years and increased with age being 275,6 
among women aged 40 years or more. 
Approximately two thirds of cancers were associated with pregnancies resulting in a delivery and 
one third with pregnancies resulting in an abortion. Italian women had an higher risk as compared 
with foreign women (respectively,  142,6 versus 90,6  per 100,000 pregnancies).  
Finally no clear trend emerged in the risk of PAC per 100,000 pregnancies and calendar year. 
The most common cancers were breast cancer (827 cases, 40.9 per 100,000 pregnancies), thyroid 
cancer (526 cases, 22,9 per 100,000 pregnancies), and lymphomas (260 cases, 11.3 per 100,000 
pregnancies). Skin cancer accounted for 449 cases (19.5 per 100,000 pregnancies), including 227 
cases of melanoma and 222 cases of other skin cancers. 
Cervical cancer was the fifth diagnosis in frequency (113 cases, 4,9 per 100,000 pregnancies ) 
 
Table 1. Number of pregnancies, pregnancy-associated cancers and risk of pregnancy-associated cancer according to selected factor.    








per  100,000 
pregnancies. 
95% confidence 
intervals of risk 
Total 2297648 3097 134,8 3111-3147 
Regions     
Piemonte  617 309 812 131,5 858,4  -  877,6 
Puglia 683 273 867 127,1 962,1  -  981,9 
Tuscany 368089 579 157,3 651     -   668,4 
Veneto 630066 839 133,2 858,4  -   877,6 
Maternal Age (yr)°°     
<30 687231 456 66,4 494,5   -   509,8 
30-34 626223 787 125,7 858,4   -   877,6 
35-39 462101 857 185,5 962,1   -   981,9 
40+ 151683 418 275,6 442,4   -    456,8 
Nationality°°     
Foreign 387472 351 90,6 389,9   -   403,2 
Italian 1476920 2106 142,6 2090    -   2120 
Pregnancy outcome°°     
Abortion/miscarriage 795769 993 124,8 962,1   -    981,9 
Delivery 1132283 1525 134,7  
Calendar year     
2003° 103987 117 112,5 123    -   131 
2005 162319 189 116,4 230,8   -   241,8 
2010 164001 203 123,8 230,8   -   241,8 
2015 129878 146 112,4 166,5    -  175,9 
 




To our knowledge only two studies in Australia and California and a study in Lombardy [4,5,7] 
have systematically analyzed PACs in a large-scale population. For PACs, as for non-PACs, the 
frequency by site differs in different areas of the world. This paper, that is among the largest 
published analysis on this issue including about 3,000,000 maternities, offers further data from a 
population of a Southern European country. In particular, it offers data from different Italian regions 
including regions of Centre and South of the country. Moreover, it covers a more recent period than 
data from Australia or California. 
Before briefly discussing our results, limitations and strengths should be considered. 
The timing of diagnosis of cancer is defined by the first hospital admission, which may introduce 
some imprecision in the timing. We are confident that our data are representative of all the 
pregnancy related cancers occurring in the considered regions among residents. In fact, all hospital 
admissions and surgical procedures are registered by law in a regional administrative database. All 
medical records were reviewed by local medical officers for administrative reasons, and thus, 
diagnostic accuracy should be warranted. 
Among the strengths of this analysis we have to consider the population-based design and the 
opportunity to analyze data collected for 10 years using similar methods in a population of more 
than 17,000,000 of inhabitants. 
The present results confirm previous estimates of incidence of PAC. 
In a large population-based linkage study conducted between 1994 and 2008 in Australia including 
more than 1,300,000 maternities, the crude incidence rate of pregnancy-associated cancer was 1.4 
per 1000 maternities. In a study conducted in California during the period 1981-1999, the 
occurrence rate of invasive malignancies was 0.9 of 1000 births. 
In the previously quoted Italian study conducted in Lombardy, a region in Northern Italy close to 
Piemonte and Veneto during the period 2001-2012, the risk of pregnancy-related cancer was 1.2 per 
1000 pregnancies. 
Analysis from the Australian population [4] has suggested that the crude incidence rate of 
pregnancy-associated cancer is increasing. We did not confirm this finding. In our study, the 
frequency of pregnancy-related cancer did not increase with calendar period despite the increasing 
maternal age at pregnancies observed in the considered period in Italy .  
The incidence of various types of cancers among women of reproductive age varies worldwide. 
Along this line, it is of interest to analyze the association between cancer and pregnancy in different 
populations, in particular in Southern European populations, which have been rarely considered in 
the published epidemiological studies.  
Breast cancer is generally reported to be the most common pregnancy related cancer in all the 
populations. It accounts for about one third of all pregnancy-related cancers. We confirm these 
findings. In an Australian study and in a Swedish population-based study, melanoma was the most 
common cancer in pregnancy [4]. Interestingly, in our population melanoma was only the fourth 
diagnosis in frequency. Part of these differences may be due to the implementation of early 
diagnosis/screening programs for melanoma in Australia and to the different incidence of this 
disease in different populations. Along this line, cervical cancer is only the fifth diagnosis despite 
the fact that in developing countries, but also in Sweden, cervical cancer has been reported among 
the most common malignant neoplasm during pregnancy [10].  
In our study, the distribution of diagnoses of PAC was not dissimilar with that reported in non-
pregnant patients of similar age [8] thus suggesting that pregnancy does not increase the incidence 
of any specific tumor. 
In conclusion, this large population-based study shows that the frequency of PAC is similar in 
different Regions of Italy without significant discrepancies with epidemiological data collected in 
Australia and Sweden. The distribution of diagnoses reflects the incidence of cancer in reproductive 
age in Italy. Finally no clear time trend in the frequency of PAC was observed in Italy during the 
last ten years. 
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